Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 65

Sort by

Sort Order Select

Journal Articles

Ultra high-risk multiple myeloma with early mortality despite quad-class and BCMA-directed therapies: Clinical and molecular insights

Binod Dhakal, Maria Hintzke, Othman Akhtar, Jamila Mammadova, Adetola Kassim, Marcelo Pasquini, Meera Mohan, Ravi Kishore Narra, Sabarinath Radhakrishnan, Fumou Sun, Anita D'Souza, Maher Albitar, Bhagirathbhai Dholaria

Blood (2025) 146 (Supplement 1): 2240.

https://doi.org/10.1182/blood-2025-2240

Published: 2025

Journal Articles

Impact of race and social deprivation on outcomes with modern day induction therapy in patients with newly diagnosed multiple myeloma: An ASH research collaborative data hub analysis

Blood (2025) 146 (Supplement 1): 2237.

https://doi.org/10.1182/blood-2025-2237

Published: 2025

Journal Articles

Immune restoration in long-term myeloma survival revealed by single-cell RNA-sequencing

Khanmi Kasomva, Kirthi Pulakanti, Josiah Murray, Kritika Yadav, Ravi Narra, Marcelo Pasquini, Anita D'Souza, Meera Mohan, Othman Akhtar, Deepak Parashar, Fumou Sun, Siegfried Janz, Binod Dhakal, Sridhar Rao

Blood (2025) 146 (Supplement 1): 5716.

https://doi.org/10.1182/blood-2025-5716

Published: 2025

Journal Articles

Comparison of clinical outcomes in multiple myeloma patients treated with chimeric antigen receptor (CAR)-T cell therapy across clinical trials: Intention-to-treat vs. per-protocol analyses

Abhishek Janardan, Pranav Jumin, Abigail Thorgerson, Ravi Kishore Narra, Othman Akhtar, Sabarinath Radhakrishnan, Marcelo Pasquini, Binod Dhakal, Anita D'Souza, Meera Mohan

Blood (2025) 146 (Supplement 1): 2800.

https://doi.org/10.1182/blood-2025-2800

Published: 2025

Journal Articles

A machine learning model to predict risk of infection in patients receiving bispecific antibody therapy for multiple myeloma

Nicholas Semenkovich, Anand George, Aishee Bag, Mansi Shah, Sabarinath Radhakrishnan, Binod Dhakal, Samer Al Hadidi, Rajshekhar Chakraborty, Carolina Schinke, Anita D'Souza, Aniko Szabo, Meera Mohan

Blood (2025) 146 (Supplement 1): 2226.

https://doi.org/10.1182/blood-2025-2226

Published: 2025

Journal Articles

PI3 kinase inhibition reduces CAR T cell trogocytosis mediated fratricide

Tarang Sharma, Maday Galeana Figueroa, Ravi Shah, Meera Mohan, Parameswaran Hari, Sabarinath Radhakrishnan

Blood (2025) 146 (Supplement 1): 4108.

https://doi.org/10.1182/blood-2025-4108

Published: 2025

Journal Articles

Low conversion rates to minimal residual disease (MRD) negativity despite improved IMWG responses with lenalidomide-isatuximab maintenance after autologous stem cell transplant (ASCT) in multiple myeloma.

Meera Mohan, Aniko Szabo, Ravi Kishore Narra, Catharine Skoog, Areyl Goff, Binod Dhakal, Othman Akhtar, Marcelo Pasquini, Sabarinath Radhakrishnan, Sridhar Rao, Subramaniam Malarkannan, Carolina Schinke, Leo Rasche, Anita D'Souza

Blood (2025) 146 (Supplement 1): 5758.

https://doi.org/10.1182/blood-2025-5758

Published: 2025

Journal Articles

Sustained remission following limited duration of bispecific antibody therapy in patients with relapsed/refractory multiple myeloma

Blood (2025) 146 (Supplement 1): 5757.

https://doi.org/10.1182/blood-2025-5757

Published: 2025

Journal Articles

Efficacy and safety of frail adults treated with ciltacabtagene autoleucel in the real-world: A CIBMTR analysis

Blood (2025) 146 (Supplement 1): 133.

https://doi.org/10.1182/blood-2025-133

Published: 2025

Journal Articles

High tolerability and favorable early outcomes with full-dose lenalidomide in older adults with newly diagnosed multiple myeloma on triplet and quadruplet therapies

Stephanie Yohay, Soyoung Kim, Mingqian Lin, Temitope Oloyede, Ravi Narra, Sabarinath Radhakrishnan, Meera Mohan, Binod Dhakal, Marcelo Pasquini, Anita D'Souza, Othman Akhtar

Blood (2025) 146 (Supplement 1): 6360.

https://doi.org/10.1182/blood-2025-6360

Published: 2025

Journal Articles

Patient perspectives and preferences for step-up dosing and treatment with teclistamab and talquetamab: Insights from a patient survey

Jay Hydren, Rachel Jensen, Jorge Arturo Hurtado Martinez, Jennifer Ahlstrom, Mason Barnes, Caitlin Costello, Gurbakhash Kaur, Meera Mohan, Francesca Cottini, Douglas Sborov, Shaji Kumar, Noopur Raje, Philippe Moreau, Maithili Deshpande, Niodita Gupta-Werner, Tonya Le Blanc, Jessica Fowler, Rahul Banerjee

Blood (2025) 146 (Supplement 1): 6354.

https://doi.org/10.1182/blood-2025-6354

Published: 2025

Journal Articles

Molecular profiling and kinetics of circulating multiple myeloma cells (CMMCs) predict resistance to bispecific antibodies (BsAbs) in relapsed and/or refractory multiple myeloma (RRMM)

Blood (2025) 146 (Supplement 1): 4012.

https://doi.org/10.1182/blood-2025-4012

Published: 2025

Journal Articles

Comparison of Healthcare Utilization in Patients Undergoing CAR T-Cell Therapy for Multiple Myeloma and Lymphoma

Kim Abbegail Tan Aldecoa, Kah Poh Loh, Yi Lee, Noha Soror, Camelia Arsene, Geetha Krishnamoorthy, Meera Mohan

Blood (2024) 144 (Supplement 1): 3652.

https://doi.org/10.1182/blood-2024-201858

Published: 2024

Journal Articles

Prevalent Treatment Patterns of Teclistamab and Talquetamab for Multiple Myeloma (MM): Experience from 609 Patients

Farheen Chunara, Mansi R. Shah, Nishi Shah, Jessica Kent, Ghulam Rehman Mohyuddin, Sabarinath V Radhakrishnan, Gurbakhash Kaur, Rajshekhar Chakraborty, Leo Rasche, Carolina Schinke, Anita D'Souza, Aniko Szabo, Meera Mohan

Blood (2024) 144 (Supplement 1): 2394.

https://doi.org/10.1182/blood-2024-201599

Published: 2024

Journal Articles

PI3 Kinase Pathway Regulates CAR T Cell Trogocytosis

Tarang Sharma, Maday Galeana Figueroa, Kishan Nyati, Meera Mohan, Parameswaran N. Hari, Sabarinath Venniyil Radhakrishnan

Blood (2024) 144 (Supplement 1): 4787.

https://doi.org/10.1182/blood-2024-202076

Published: 2024

Journal Articles

The Efficacy of Teclistamab in Multiple Myeloma Patients with Secondary Plasma Cell Leukemia

Asis Shrestha, Sharmilan Thanendrarajan, Aishee Bag, Binod Dhakal, Maurizio Zangari, Samer Al Hadidi, Suzanne Lentzsch, Frits van Rhee, Anita D'Souza, Rajshekhar Chakraborty, Nishi Shah, Mansi R. Shah, Meera Mohan, Carolina Schinke

Blood (2024) 144 (Supplement 1): 6994.

https://doi.org/10.1182/blood-2024-210478

Published: 2024

Journal Articles

Upfront Use of Anti-CD38 Monoclonal Antibodies Is Associated with Improvement in Renal Failure in Multiple Myeloma: A Flatiron Real World Analysis from 2010 to 2023

Adeel M Khan, Zimu Gong, Tanushree Prasad, Rahul Banerjee, Srija Shankar, Aimaz Afrough, Larry D Anderson, Jr., Meera Mohan, Gurbakhash Kaur

Blood (2024) 144 (Supplement 1): 3792.8.

https://doi.org/10.1182/blood-2024-210930

Published: 2024

Journal Articles

CD47-CD138 Bispecific Antibody Exhibits Selective Targeting of Multiple Myeloma

Maday Galeana Figueroa, Kishan Nyati, Tarang Sharma, Binod Dhakal, Meera Mohan, Parameswaran N. Hari, Sabarinath Venniyil Radhakrishnan

Blood (2024) 144 (Supplement 1): 4812.

https://doi.org/10.1182/blood-2024-208382

Published: 2024

Journal Articles

MRD-Guided Sequential Therapy for Deep Response in Newly Diagnosed Multiple Myeloma (NDMM)- Master-2 Trial

Blood (2024) 144 (Supplement 1): 2000.1.

https://doi.org/10.1182/blood-2024-200210

Published: 2024

Journal Articles

Effects of Intravenous Immunoglobulin Supplementation (IVIG) on Infections in Recipients of Teclistamab Therapy for Multiple Myeloma (MM): A Multi-Institutional Study

Blood (2024) 144 (Supplement 1): 256.

https://doi.org/10.1182/blood-2024-199374

Published: 2024

Update search

NARROW

Publications

Format

Article Type

Topics

Date

Availability

Ultra high-risk multiple myeloma with early mortality despite quad-class and BCMA-directed therapies: Clinical and molecular insights

Impact of race and social deprivation on outcomes with modern day induction therapy in patients with newly diagnosed multiple myeloma: An ASH research collaborative data hub analysis

Immune restoration in long-term myeloma survival revealed by single-cell RNA-sequencing

Comparison of clinical outcomes in multiple myeloma patients treated with chimeric antigen receptor (CAR)-T cell therapy across clinical trials: Intention-to-treat vs. per-protocol analyses

A machine learning model to predict risk of infection in patients receiving bispecific antibody therapy for multiple myeloma

PI3 kinase inhibition reduces CAR T cell trogocytosis mediated fratricide

Low conversion rates to minimal residual disease (MRD) negativity despite improved IMWG responses with lenalidomide-isatuximab maintenance after autologous stem cell transplant (ASCT) in multiple myeloma.

Sustained remission following limited duration of bispecific antibody therapy in patients with relapsed/refractory multiple myeloma

Efficacy and safety of frail adults treated with ciltacabtagene autoleucel in the real-world: A CIBMTR analysis

High tolerability and favorable early outcomes with full-dose lenalidomide in older adults with newly diagnosed multiple myeloma on triplet and quadruplet therapies

Patient perspectives and preferences for step-up dosing and treatment with teclistamab and talquetamab: Insights from a patient survey

Molecular profiling and kinetics of circulating multiple myeloma cells (CMMCs) predict resistance to bispecific antibodies (BsAbs) in relapsed and/or refractory multiple myeloma (RRMM)

Comparison of Healthcare Utilization in Patients Undergoing CAR T-Cell Therapy for Multiple Myeloma and Lymphoma

Prevalent Treatment Patterns of Teclistamab and Talquetamab for Multiple Myeloma (MM): Experience from 609 Patients

PI3 Kinase Pathway Regulates CAR T Cell Trogocytosis

The Efficacy of Teclistamab in Multiple Myeloma Patients with Secondary Plasma Cell Leukemia

Upfront Use of Anti-CD38 Monoclonal Antibodies Is Associated with Improvement in Renal Failure in Multiple Myeloma: A Flatiron Real World Analysis from 2010 to 2023

CD47-CD138 Bispecific Antibody Exhibits Selective Targeting of Multiple Myeloma

MRD-Guided Sequential Therapy for Deep Response in Newly Diagnosed Multiple Myeloma (NDMM)- Master-2 Trial

Effects of Intravenous Immunoglobulin Supplementation (IVIG) on Infections in Recipients of Teclistamab Therapy for Multiple Myeloma (MM): A Multi-Institutional Study

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only